## What did this study look at?

The study looked at how secukinumab treatment affected different types of pain and stiffness in patients with axial spondyloarthritis (axSpA) for 5 years. The results were compared to patients who received a placebo (a treatment containing no active ingredients). The study was designed to check if any changes in these symptom scores were because of secukinumab treatment.

### Design of the study

<table>
<thead>
<tr>
<th>Date: November 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full abstract title: Subcutaneous secukinumab 150 mg provides sustained relief in total and specific pain measures over 5 years in patients with axial spondyloarthritis (nr-axSpA) treated with secukinumab.</td>
</tr>
</tbody>
</table>

### What did this study find?

Improvements were sustained from Week 16 to 5 years in patients treated with secukinumab. In the questionnaire used to assess pain, stiffness and fatigue, a high score indicated “worse symptom control” and low score indicated “good symptom control.”

### What was the study about?

Axial spondyloarthritis (axSpA) is a group of long-term inflammatory diseases of the spine that do not appear on X-ray. Inflammation of the spine or vertebrae is one of the hardest symptoms to deal with. Other symptoms of axSpA include:

- Fatigue
- Increased morning stiffness
- Pain at night that’s bad enough to wake you up
- Difficulty functioning in daily life

AxSpA symptoms can affect people’s daily lives and may limit their ability to take part in normal activities. Ankylosing spondylitis (AS)

The symptoms of axSpA include:

- Fatigue
- Increased morning stiffness
- Pain at night that’s bad enough to wake you up
- Difficulty functioning in daily life

### Who sponsored this study?

This study was sponsored by Novartis. For a complete list of sponsors and sources of funding, see the full ACR 2020 scientific abstract.

### Further information

For more information, please visit [clinicaltrials.gov/ct2/show/NCT01649375](https://clinicaltrials.gov/ct2/show/NCT01649375)